ReviewClinics (Sao Paulo, Brazil)2026
Efficacy and safety of tofacitinib in ankylosing spondylitis patients: a systematic review and meta-analysis.
Review in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTofacitinib, an oral Janus Kinase (JAK) inhibitor, exhibits promising therapeutic potential for Ankylosing Spondylitis (AS). This meta-analysis aimed to assess its efficacy and safety in AS patients.
methodsPubMed, Embase, Web of Science and Cochrane Library, were systematically searched for relevant studies until May 21, 2025. Literature screening was conducted using EndNote 21. Risk of bias for encompassed Randomized Controlled Trials (RCTs) was examined via the Cochrane Risk of Bias tool (RoB2.0). The quality of cohort studies was rated using the Newcastle-Ottawa Scale (NOS). Meta-analysis was performed via Stata 18.0.
resultsFive studies were encompassed: three RCTs and two cohort studies. Regarding primary efficacy outcomes, tofacitinib significantly increased response rates for ASAS20 (Relative Risk [RR = 1.96]; 95% Confidence Intervals [95% CI: 1.74‒2.21]), ASAS40 (RR = 1.88; 95% CI: 1.48‒2.40) and ASAS-PR (RR = 2.55; 95% CI: 1.82‒3.58). Regarding Disease Activity (DA), tofacitinib demonstrated significant benefits in achieving BASDAI50 (RR = 1.90; 95% CI: 1.64‒2.20) and ASDAS. Physical Function (PF) and Quality of Life (QoL) outcomes were also notably ameliorated in the intervention group. Subgroup analysis indicated that 5 mg dosage and 16-week treatment duration exhibited the most favorable efficacy trends across most outcomes. Overall rates of Adverse Events (AEs) and Serious Adverse Events (SAEs) were similar between tofacitinib and placebo groups. However, the risk of Upper Respiratory Tract Infection (URTI) was significantly higher in the tofacitinib group (RR = 2.15; 95% CI: 1.27‒3.63).
conclusionTofacitinib is an effective and generally well-tolerated active AS therapy, significantly ameliorating DA, PF, and QoL, although it may elevate the risk of URTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.